Ipsen posts 3rd-qtr sales growth of over 20%

25 October 2018

French drugmaker Ipsen (Euronext: IPN) this morning announced sales for the third quarter of 2018, posting strong growth, but failed to impress the market as its share fell 2.35% to 120.65 euros(at constant currency) in early trading.

Group sales growth for the quarter of 20.2% to 555.9 million euros was driven by Specialty Care sales growth of 24.2% to 484,1 million,reflecting strong momentum for Somatuline (lanreotide) and Dysport (abobotulinumtoxinA)continued sequential sales growth for Cabometyx (cabozantinib)and Onivyde (irinotecan liposome), and growth of Consumer Healthcare sales to 71.9 euros.

Full Year 2018 guidance was confirmed with group sales growth of greater than 19.0%and core operating margin of around 29.0% of sales

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK